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Abstract 
The envelope proteins of many viruses are glycosylated, where the glycans on the virion 
surface have been shown to be important, in addition to their strictly structural role, in 
various aspects of the virus life cycle, such as receptor-binding and escape from antibody 
recognition. Dengue virus (DENV) is in terms of human disease frequency the most 
important member of the flaviviruses, a group of small, enveloped, plus-strand RNA 
viruses. The four DENV serotypes differ from all other flaviviruses by the presence of 
two glycans on the envelope (E) protein, one linked to Asn-153, a glycosylation which is 
well conserved among the flaviviruses, and a second linked to Asn-67, which is unique to 
DENY. While the presence of glycan at Asn-153 has been shown by others to influence 
fusion of viral with cellular membranes, infectivity, assembly and/or release and 
virulence, the glycan at Asn-67 has been suggested to be critical in virus attachment to 
the cell surface molecule, DC-SIGN, a putative cellular receptor for DENV. In this study, 
I have used a reverse genetics approach to prevent glycosylation at Asn-67, Asn-153, or 
both carbohydrate acceptor sites, in order to investigate their physiological function(s). 
Single or multiple point mutation were introduced at the Asn-153 and Asn-67 
glycosylation sites, respectively, on the E protein ofDENV-2 strains NGC and PUO-218, 
using two infectious cDNA clones. DENV -2 strain, NGC, is a laboratory-adapted virus, 
while strain PUO-218 is a low-passage natural isolate from Toxorhynchites splendens 
mosquitoes. 
In Chapter 3, I show that removal of the Asn-153-linked glycan in the context of the E 
protein of both DENV-2 strains impaired virus growth in vertebrate cells. This was 
reflected in reduced plaque size on Vero cell monolayers, although electroporation 
efficiencies for the different variants were not reduced relative to that of parental 
infectious clone-derived RNA. Removal of the Asn-67-linked glycan revealed a more 
detrimental impact on growth phenotype in vertebrate cells, which was influenced by the 
E protein background and the substitution chosen to prevent glycosylation. A T69A 
mutation introduced into the PUO-218 E protein produced a viable virus, albeit one with 
x 
a very small plaque phenotype on Vero cells. Interestingly, when other substitutions 
preventing Asn-67-linked glycan addition were introduced into the PUO-218 E protein, 
virus viability was improved in the order: T69V > T69L, N67Q > N67D > T69A 
(Chapter 5). Insertion of the T69A mutation into the E protein of DENV-2, NGC strain, 
severely limited virus viability in vertebrate cells and following passage in Vero cells 
only viruses with a pseudo-reversion (T69V) or compensatory mutation (K126T) could 
be recovered. The latter change introduced a novel carbohydrate acceptor site into the 
NGC E protein (AsnI24-MetJ25-ThrI26), which was utilised. Passage in Vero cells of the 
loss-of-Asn-67-linked-glycan variant, rPUO.T69A, also produced a pseudo-revertant 
with the compensatory mutation, N 124S, in the E protein. This mutation significantly 
increased plaque size on Vero cells, but did not alter glycosylation status. 
Growth properties of loss-of-Asn-153-linked-glycan variants in vertebrate (Vero) and 
mosquito (C6/36) cells were further analysed in Chapter 4. Absence of the Asn-153-
linked glycan in the context of the NGC E protein reduced growth in Vero cells by -10-
fold in terms of virus particle production and release measured by qRT-PCR. In contrast, 
virus particle production and release of the PUO-218 loss-of-Asn-153-linked-glycan 
variant was not markedly different from that of the parent virus. Loss of the Asn-153-
linked glycan reduced the specific infectivity for Vero cells but increased that for C6/36 
cells for both variants. I show that the latter may be due to an increase in the pH threshold 
for fusion as a result of loss of the Asn-153-1inked glycan and discuss that this E protein 
change may allow virus uptake into some cell types by cell surface fusion. 
In Chapter 5, the requirement for the Asn-67-linked E protein glycan for virus production 
in mammalian cells was investigated by introducing infectious RNA into Vero cells by 
electroporation and measuring virion assembly and release by qRT -PCR. These 
experiments were undertaken in view of the finding by two groups published during the 
course of my study, Mondotte et al. (2007) and Bryant et aL (2007), that loss-of-Asn-67-
linked glycosylation on the DENV -2 E protein is lethal for virus growth in mammalian 
cells as a result of a defect in virus assembly/release. My results clearly demonstrate that 
Xl 
this conclusion is not valid for the E protein of DENV-2 strain, PUO-218: I find that 
loss-of-Asn-67-linked-glycan mutant, rPUO.T69V, is comparable to the parent virus in 
terms of particle assembly and release and that the N67Q mutation used in the published 
work reduces but does not abolish particle assembly and release, when in the context of 
the PUO-218 E protein. 
I also show that removal of both glycans from the DENV-2 E protein prevents the 
recovery of viable virus with a stable mutant genotype (Chapters 3 and 5). Nevertheless, 
given the importance of strain origin and type of substitution used for deletion of the 
carbohydrate acceptor sites that I have demonstrated in this thesis, it is likely that the 
engineering of a viable DENV variant lacking both E protein glycans is feasible. 
